阿斯利康与血液病<\/b><\/u><\/p> \n
借助在肿瘤领域的优势，阿斯利康公司将血液肿瘤确立为四个重点肿瘤疾病领域之一。目前公司血液业务已有两种药物获得美国FDA批准，并且具有强劲的全球研发计划，广泛探索可能的血液肿瘤治疗方法。Acerta制药是阿斯利康的血液学研发子公司。阿斯利康与志同道合的科研公司合作，致力于推动药物的研发工作，以解决未被满足的需求。<\/p> \n
阿斯利康与肿瘤学<\/b><\/u><\/p> \n
阿斯利康在肿瘤领域的研究源远流长，我们迅速壮大的新药组合将改变患者的生活，并为公司未来发展带来无限可能。凭借2014至2020年间至少6款新药的上市，以及一条由在研小分子和生物制剂充实的研发管线，我们将致力于推动肿瘤业务成为阿斯利康的关键增长驱动力，并将研究集中在肺、卵巢、乳腺和血液四个疾病领域的肿瘤。除核心能力外，我们还积极寻求创新的伙伴关系和外部投资，加速实现我们的战略，比如我们投资Acerta制药公司用于血液病研究。<\/p> \n
通过运用肿瘤免疫疗法、肿瘤的驱动基因及耐药机制、DNA损伤修复和抗体药物复合体四大科学平台，倡导个体化组合的发展，阿斯利康以期重新定义癌症治疗并在未来攻克癌症。<\/p> \n
声明<\/i><\/p> \n
这些研究中的药品用法尚未在中国获批适应症，阿斯利康不推荐任何未被批准的药品使用。<\/i><\/p> \n
关于阿斯利康<\/b><\/u><\/p> \n
阿斯利康是一家以创新为驱动的全球性生物制药企业，专注于研发、生产和销售处方类药品，重点关注五大治疗领域 -- 肿瘤、心血管、肾脏、代谢以及呼吸相关疾病的治疗。阿斯利康的业务遍布100多个国家，创新药物惠及全球数百万患者。更多信息请访问astrazeneca.com<\/a><\/u>或者关注我们的官方Twitter @AstraZeneca<\/u>。<\/p> \n 媒体事务<\/b><\/span><\/p> <\/td> \n Gonzalo Viña <\/span><\/p> <\/td> \n +44 203 749 5916<\/span><\/p> <\/td> \n <\/tr> \n Rob Skelding<\/span><\/p> <\/td> \n Oncology<\/span><\/p> <\/td> \n +44 203 749 5821<\/span><\/p> <\/td> \n <\/tr> \n Rebecca Einhorn<\/span><\/p> <\/td> \n Oncology<\/span><\/p> <\/td> \n +1 301 518 4122<\/span><\/p> <\/td> \n <\/tr> \n Matt Kent<\/span><\/p> <\/td> \n BioPharma<\/span><\/p> <\/td> \n +44 203 749 5906<\/span><\/p> <\/td> \n <\/tr> \n Jennifer Hursit<\/span><\/p> <\/td> \n Other <\/span><\/p> <\/td> \n +44 203 749 5762<\/span><\/p> <\/td> \n <\/tr> \n Christina Malmberg Hägerstrand<\/span><\/p> <\/td> \n Sweden<\/span><\/p> <\/td> \n +46 8 552 53 106<\/span><\/p> <\/td> \n <\/tr> \n Michele Meixell<\/span><\/p> <\/td> \n US<\/span><\/p> <\/td> \n +1 302 885 2677<\/span><\/p> <\/td> \n <\/tr> \n Investor Relations<\/b>投资事务<\/b><\/span><\/p> <\/td> \n Thomas Kudsk Larsen<\/span><\/p> <\/td> \n +44 203 749 5712<\/span><\/p> <\/td> \n <\/tr> \n Henry Wheeler<\/span><\/p> <\/td> \n Oncology<\/span><\/p> <\/td> \n +44 203 749 5797<\/span><\/p> <\/td> \n <\/tr> \n Christer Gruvris<\/span><\/p> <\/td> \n BioPharma (cardiovascular; metabolism)<\/span><\/p> <\/td> \n +44 203 749 5711<\/span><\/p> <\/td> \n <\/tr> \n Nick Stone<\/span><\/p> <\/td> \n BioPharma (respiratory; renal)<\/span><\/p> <\/td> \n +44 203 749 5716<\/span><\/p> <\/td> \n <\/tr> \n Josie Afolabi<\/span><\/p> <\/td> \n Other medicines<\/span><\/p> <\/td> \n +44 203 749 5631<\/span><\/p> <\/td> \n <\/tr> \n Craig Marks<\/span><\/p> <\/td> \n Finance, fixed income<\/span><\/p> <\/td> \n +44 7881 615 764<\/span><\/p> <\/td> \n <\/tr> \n Jennifer Kretzmann<\/span><\/p> <\/td> \n Corporate access, retail investors<\/span><\/p> <\/td> \n +44 203 749 5824<\/span><\/p> <\/td> \n <\/tr> \n US toll-free<\/span><\/p> <\/td> \n +1 866 381 72 77<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n 图片 - https:\/\/photos.prnasia.com\/prnh\/20191210\/2666033-1-a?lang=1<\/a> \n \n
\n
<\/td> \n
<\/td> \n <\/tr> \n \n
<\/td> \n \n \n \n \n \n \n \n
<\/td> \n
<\/td> \n
<\/td> \n <\/tr> \n \n
<\/td> \n
<\/td> \n <\/tr> \n \n
<\/td> \n \n \n \n \n \n \n \n
<\/td> \n
图片 - https:\/\/photos.prnasia.com\/prnh\/20191210\/2666033-1-b?lang=1<\/a>
<\/p>"];
$("#dvExtra").html(content_array[0]);})();